X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1956) 1956
Book Review (245) 245
Publication (92) 92
Newsletter (21) 21
Magazine Article (18) 18
Book Chapter (12) 12
Conference Proceeding (5) 5
Newspaper Article (3) 3
Reference (2) 2
Transcript (2) 2
Book / eBook (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1502) 1502
humans (1069) 1069
phenylalanine (833) 833
male (617) 617
female (550) 550
animals (475) 475
adult (359) 359
phenylalanine - analogs & derivatives (323) 323
middle aged (269) 269
phenylalanine - blood (248) 248
analysis (234) 234
phenylketonuria (234) 234
amino acids (211) 211
pharmacology & pharmacy (211) 211
phenylalanine - therapeutic use (202) 202
rats (199) 199
physiological aspects (181) 181
aged (164) 164
biochemistry & molecular biology (160) 160
metabolism (160) 160
phenylalanine ammonia-lyase (159) 159
tyrosine (158) 158
mice (157) 157
endocrinology & metabolism (156) 156
phenylalanine - adverse effects (156) 156
enzymes (153) 153
abridged index medicus (151) 151
plant sciences (132) 132
child (131) 131
phenylalanine - pharmacology (131) 131
research (129) 129
adolescent (128) 128
proteins (127) 127
phenylalanine - metabolism (126) 126
phenylalanine - administration & dosage (122) 122
ammonia (116) 116
n-formylmethionine leucyl-phenylalanine - pharmacology (114) 114
metabolites (113) 113
genetics & heredity (112) 112
dose-response relationship, drug (110) 110
diet (108) 108
treatment outcome (105) 105
medicine, research & experimental (104) 104
care and treatment (103) 103
pediatrics (103) 103
oxidative stress (101) 101
time factors (98) 98
double-blind method (95) 95
life sciences (90) 90
phenols (88) 88
plants (87) 87
health aspects (86) 86
pregnancy (86) 86
toxicology (86) 86
medicine & public health (85) 85
diabetes mellitus, type 2 - drug therapy (84) 84
oncology (84) 84
gene expression (83) 83
child, preschool (82) 82
nateglinide (81) 81
phenylketonurias - drug therapy (81) 81
antioxidants (80) 80
biosynthesis (80) 80
nutrition & dietetics (80) 80
hypoglycemic agents - therapeutic use (79) 79
phenylketonurias - blood (79) 79
phenylketonurias - diet therapy (79) 79
tryptophan (79) 79
amino-acids (78) 78
cyclohexanes - therapeutic use (78) 78
food science & technology (78) 78
internal medicine (77) 77
biopterin - analogs & derivatives (76) 76
expression (76) 76
growth (76) 76
neutrophils - drug effects (76) 76
biotechnology & applied microbiology (74) 74
neurosciences (74) 74
children (73) 73
infant (71) 71
infant, newborn (71) 71
phenylalanine - pharmacokinetics (69) 69
physiology (67) 67
glucose (66) 66
medicine (65) 65
tetrahydrobiopterin (65) 65
drug therapy (64) 64
tyrosine - blood (61) 61
brain (60) 60
cancer (60) 60
young adult (60) 60
article (59) 59
metabolomics (59) 59
multidisciplinary sciences (59) 59
stress (59) 59
biochemistry, general (58) 58
peroxidase (57) 57
studies (57) 57
disease models, animal (56) 56
mass spectrometry (55) 55
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1909) 1909
German (71) 71
Japanese (9) 9
French (8) 8
Russian (4) 4
Chinese (3) 3
Spanish (3) 3
Italian (2) 2
Polish (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 16, pp. 1477 - 1490
In this large clinical trial, the angiotensin-receptor blocker valsartan reduced the risk of diabetes in patients with impaired glucose tolerance. However, the... 
FASTING GLUCOSE | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | LIFE-STYLE INTERVENTIONS | DISEASE | PREVENTION | COMPONENTS | IMPAIRED GLUCOSE-TOLERANCE | MELLITUS | CONVERTING-ENZYME-INHIBITORS | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Tetrazoles - adverse effects | Valine - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Cardiovascular disease | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 16, pp. 1463 - 1476
Among patients with impaired glucose tolerance, the short-acting insulin secretagogue nateglinide did not reduce the incidence of diabetes over the course of 5... 
TRIAL | MEDICINE, GENERAL & INTERNAL | LIFE-STYLE | DIET | INSULIN-SECRETION | DISEASE | PREVENTION | IMPAIRED GLUCOSE-TOLERANCE | ACARBOSE | MELLITUS | NIDDM | Follow-Up Studies | Phenylalanine - adverse effects | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Treatment Failure | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Cyclohexanes - adverse effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Kaplan-Meier Estimate | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Hypoglycemic Agents - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Nateglinide | Studies | Cardiovascular disease | Index Medicus | Abridged Index Medicus | Clinical Medicine | Allmänmedicin | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | General Practice
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 1, pp. 14 - 23
Journal Article